{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:50:06Z","timestamp":1776534606612,"version":"3.51.2"},"reference-count":164,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton\u2019s tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology.<\/jats:p>","DOI":"10.3390\/life10120344","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T20:56:57Z","timestamp":1607893017000},"page":"344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cardiotoxicity of Novel Targeted Hematological Therapies"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"Clinical Pharmacology, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"IRCCS Neuromed (Mediterranean Neurological Institute), 86077 Pozzilli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, Baronissi, 84081 Salerno, Italy"},{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi D\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e009122","DOI":"10.1161\/JAHA.118.009122","article-title":"Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: A DCOG-LATER Study","volume":"8","author":"Feijen","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: Understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Galderisi, M., Santoro, C., Bossone, E., and Mancusi, C. (2020). Rationale and proposal for cardio-oncology services in Italy. J. Cardiovasc. Med.","DOI":"10.2459\/JCM.0000000000001087"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ehjci\/jez194","article-title":"Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction","volume":"20","author":"Santoro","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001753","DOI":"10.1161\/CIRCGEN.117.001753","article-title":"Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk","volume":"11","author":"Linschoten","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bmt.1704763","article-title":"Cardiac toxicity of high-dose chemotherapy","volume":"35","author":"Morandi","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2141.2003.04541.x","article-title":"A selective history of the therapy of Hodgkin\u2019s disease","volume":"122","author":"DeVita","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase\u2014Role and significance in Cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/sj.onc.1205317","article-title":"Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease","volume":"21","author":"Scheijen","year":"2002","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Giudice, V., Mensitieri, F., Izzo, V., Filippelli, A., and Selleri, C. (2020). Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093252"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.93.20.10966","article-title":"An essential role for Bruton\u2019s [corrected] tyrosine kinase in the regulation of B-cell apoptosis","volume":"93","author":"Anderson","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/sj.onc.1206425","article-title":"BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells","volume":"22","author":"Glassford","year":"2003","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-013-1967-y","article-title":"The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia","volume":"93","author":"Brachtl","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0092-8674(89)90775-7","article-title":"Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes","volume":"59","author":"Osborn","year":"1989","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2003-07-2281","article-title":"Prognosis at diagnosis: Integrating molecular biologic insights into clinical practice for patients with CLL","volume":"103","author":"Shanafelt","year":"2004","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"A14587","DOI":"10.1161\/circ.132.suppl_3.14587","article-title":"Proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton\u2019s tyrosine kinase (BTK) used in cancer therapy (abstr)","volume":"132","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/19336950.2019.1697127","article-title":"PI3K\u03b1 in cardioprotection: Cytoskeleton, late Na+ current, and mechanism of arrhythmias","volume":"13","author":"Zhabyeyev","year":"2019","journal-title":"Channels"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fphar.2015.00169","article-title":"Phosphoinositide 3-kinase: Friend and foe in cardiovascular disease","volume":"6","author":"Ghigo","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.hrthm.2015.01.044","article-title":"Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K\/AKT\/eNOS signaling pathway activation","volume":"12","author":"Chong","year":"2015","journal-title":"Heart Rhythm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","author":"Psaty","year":"1997","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11864-020-00764-6","article-title":"Cardiovascular Toxicities of Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"21","author":"Alomar","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ejh.13290","article-title":"Sudden ventricular fibrillation and death during ibrutinib therapy-A case report","volume":"103","author":"Bernardeschi","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1073274820931808","DOI":"10.1177\/1073274820931808","article-title":"Electrocardiographic Changes Associated With Ibrutinib Exposure","volume":"27","author":"Fradley","year":"2020","journal-title":"Cancer Control"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated With Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.2019002805","article-title":"Cardiovascular adverse events of ibrutinib","volume":"134","author":"Ahn","year":"2019","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Caldeira, D., Alves, D., Costa, J., Ferreira, J.J., and Pinto, F.J. (2019). Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211228"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1916326","DOI":"10.1001\/jamanetworkopen.2019.16326","article-title":"Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia","volume":"2","author":"Roeker","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/OTT.S102573","article-title":"Idelalisib for the treatment of indolent non-Hodgkin lymphoma: A review of its clinical potential","volume":"9","author":"Barrientos","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma","volume":"21","author":"Assouline","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach","volume":"102","author":"Koopmans","year":"2017","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040620715625966","article-title":"The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"7","author":"Nair","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_50","first-page":"A11835","article-title":"Abstract 11835: Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib; Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia","volume":"138","author":"Mahida","year":"2018","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib; a PI3K inhibitor; in relapsed or refractory; indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clml.2018.11.021","article-title":"Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas","volume":"19","author":"Cheson","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological Role and Therapeutic Potential of IDH Mutations in Cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1078155219865934","article-title":"Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review","volume":"26","author":"Patel","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CE.S172912","article-title":"Enasidenib in the treatment of relapsed\/refractory acute myeloid leukemia: An evidence-based review of its place in therapy","volume":"14","author":"Galkin","year":"2019","journal-title":"Core Evid."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2011-02-335042","article-title":"Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"key":"ref_62","unstructured":"Rodgers, G.P., and Young, N.S. (2018). The Bethesda Handbook of Clinical Hematology, Lippincott Williams & Wilkins (LWW). [4th ed.]."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","article-title":"How I treat myelofibrosis after failure of JAK inhibitors","volume":"132","author":"Pardanani","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"von Bubnoff, N., Ihorst, G., Grishina, O., R\u00f6thling, N., Bertz, H., Duyster, J., Finke, J., and Zeiser, R. (2018). Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5045-7"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16609","DOI":"10.1038\/s41598-019-53056-x","article-title":"Metabolic Effects of JAK1\/2 Inhibition in Patients with Myeloproliferative Neoplasms","volume":"9","author":"Sapre","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.90","article-title":"Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study","volume":"3","author":"Punwani","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2169\/internalmedicine.3528-19","article-title":"Long-term Effects of the Janus Kinase 1\/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis","volume":"59","author":"Miyawaki","year":"2020","journal-title":"Intern. Med."},{"key":"ref_70","first-page":"1","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"2020","author":"Talpaz","year":"2020","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: Moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.2147\/CMAR.S212559","article-title":"Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis","volume":"11","author":"Bewersdorf","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_75","first-page":"357027","article-title":"Imatinib: A breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"ref_76","first-page":"1248","article-title":"Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Marcucci","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Grazette","year":"2006","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2006.067710","article-title":"Cardiotoxicity of imatinib mesylate: An extremely rare phenomenon or a major side effect?","volume":"66","author":"Distler","year":"2007","journal-title":"Ann. Rheum Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12012-018-9453-3","article-title":"Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?","volume":"18","author":"Francisco","year":"2018","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ejhf.58","article-title":"Ageing is a risk factor in imatinib mesylate cardiotoxicity","volume":"16","author":"Maharsy","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_85","first-page":"e4","article-title":"Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy","volume":"1","author":"Xu","year":"2009","journal-title":"Hematol. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2016.09.009","article-title":"Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?","volume":"168","author":"Magdy","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Kantarjian","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.3324\/haematol.2011.041319","article-title":"The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)","volume":"96","author":"Visani","year":"2011","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_94","first-page":"4733","article-title":"Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation","volume":"34","author":"Shopp","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2013.04.027","article-title":"Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes","volume":"272","author":"Doherty","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_100","first-page":"A11853","article-title":"Abstract 11853: Cardiovascular Adverse Events Associated With First, Second and Third Generation Tyrosine Kinase Inhibitors Used in Treatment of Chronic Myeloid Leukemia","volume":"138","author":"Mahida","year":"2018","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41598-018-27767-6","article-title":"T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system","volume":"8","author":"Tamai","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1634\/theoncologist.2019-0976","article-title":"The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation","volume":"25","author":"Tzogani","year":"2020","journal-title":"Oncologist"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1158\/1538-7445.AM2019-3889","article-title":"Abstract 3889: Population pharmacokinetic\/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients","volume":"79","author":"Fostvedt","year":"2019","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00280-012-1825-y","article-title":"Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers","volume":"69","author":"Dutreix","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_115","first-page":"73","article-title":"Midostaurin: An emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Gallogly","year":"2016","journal-title":"J. Blood Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/wjon1232","article-title":"Midostaurin-Related Interstitial Lung Injury in FLT3+ Acute Myeloid Leukemia Post-Allogeneic Transplant","volume":"10","author":"Vaidya","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Yin, J., Wei, J., and Shang, Z. (2014). Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087671"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0735-1097(20)31350-4","article-title":"Cardiovascular outcomes following bortezomib reinitiation after congestive heart failure diagnosis in multiple myeloma","volume":"75","author":"Shah","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1182\/blood.V126.23.3046.3046","article-title":"Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1128 Patients","volume":"126","author":"Reneau","year":"2015","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V126.23.4265.4265","article-title":"Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center","volume":"126","author":"Land","year":"2015","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: A case report and review of the literature","volume":"128","author":"Bockorny","year":"2012","journal-title":"Acta Haematol."},{"key":"ref_127","first-page":"20","article-title":"Bortezomib-induced Severe Congestive Heart Failure","volume":"1","author":"Jerkins","year":"2010","journal-title":"Cardiol. Res."},{"key":"ref_128","first-page":"3456287","article-title":"Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity","volume":"2016","author":"Diwadkar","year":"2016","journal-title":"Case Rep. Cardiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_130","first-page":"4","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardiooncology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10245332.2017.1328165","article-title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: Practical management aspects from two case studies","volume":"22","author":"Jakubowiak","year":"2017","journal-title":"Hematology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy\u2014Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.3389\/fimmu.2018.03171","article-title":"Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma","volume":"9","author":"Marcatti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular Complications of Novel Multiple Myeloma Treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.24599","article-title":"Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1790 patients","volume":"92","author":"Reneau","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis. A meta-analysis","volume":"97","author":"Shamseddeen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"a026948","DOI":"10.1101\/cshperspect.a026948","article-title":"DNA Hypomethylating Drugs in Cancer Therapy","volume":"7","author":"Sato","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_145","first-page":"1248","article-title":"A Risk-Scoring System to Predict Heart Failure Onset during Treatment of Myelodysplastic Syndrome with Azacitidine","volume":"6","author":"Kambara","year":"2019","journal-title":"Ann. Hematol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/phar.1733","article-title":"Azacitidine-Induced Pericarditis: A Case Series","volume":"36","author":"Newman","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_147","first-page":"3953579","article-title":"Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy","volume":"2018","author":"Agasthi","year":"2018","journal-title":"Case Rep. Cardiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","article-title":"Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets","volume":"8","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12026-007-0073-4","article-title":"Monoclonal antibody mechanisms of action in cancer","volume":"39","author":"Weiner","year":"2007","journal-title":"Immunol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig","year":"2008","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun. Highlights"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: Are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"939","DOI":"10.36290\/vnl.2018.131","article-title":"CD38 targeted treatment for multiple myeloma","volume":"64","year":"2018","journal-title":"Vnitr. Lek."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: Patients\u2019 selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"MAbs"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"De Re, V., Caggiari, L., Repetto, O., Mussolin, L., and Mascarin, M. (2019). Classical Hodgkin\u2019s Lymphoma in the Era of Immune Checkpoint Inhibition. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101596"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_161","first-page":"521","article-title":"Polatuzumab Vedotin for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients","volume":"11","author":"Douglas","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Trapani, D., Zagami, P., Nicol\u00f2, E., Pravettoni, G., and Curigliano, G. (2020). Management of Cardiac Toxicity Induced by Chemotherapy. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092885"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13063-019-3963-6","article-title":"Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: Study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial)","volume":"21","author":"Carrasco","year":"2020","journal-title":"Trials"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/12\/344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:46Z","timestamp":1760179426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/12\/344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":164,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["life10120344"],"URL":"https:\/\/doi.org\/10.3390\/life10120344","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}